Welcome to our dedicated page for Optinose news (Ticker: OPTN), a resource for investors and traders seeking the latest updates and insights on Optinose stock.
OptiNose, Inc. (NASDAQ: OPTN), founded in 2010 and headquartered in Yardley, Pennsylvania, is a global specialty pharmaceutical company focused on improving the lives of patients treated by ear, nose, and throat (ENT) and allergy specialists. The company is known for its innovative approach to pharmaceutical development and commercialization, aiming to offer value to both the healthcare system and its stakeholders.
OptiNose's flagship product is XHANCE (fluticasone propionate) nasal spray, a unique therapeutic that utilizes the proprietary Exhalation Delivery System (EDS). This system delivers a topical corticosteroid deep into the nasal passages to treat chronic rhinosinusitis with nasal polyps. Unlike traditional nasal sprays, XHANCE targets inflammation high and deep within the nasal passages, reaching areas previously inaccessible by standard treatments.
Recently, XHANCE was approved by the FDA for the treatment of chronic rhinosinusitis without nasal polyps, expanding its potential patient base significantly. This approval was backed by robust clinical data from the ReOpen program, consisting of two global, randomized, double-blind, placebo-controlled Phase 3 trials. These trials demonstrated significant improvement in both symptoms and inflammation for patients with chronic sinusitis, with or without nasal polyps. Some common adverse reactions included epistaxis, headache, and nasopharyngitis, consistent with its labeled safety profile.
OptiNose continues to innovate, working on faster and cost-effective product developments and exploring new commercial models. The company collaborates with ENT and allergy specialists to bring breakthrough treatments to patients, focusing on efficiency and effectiveness in all its operations. OptiNose's commitment to values and ethical practices ensures their dedication to patient care and improved health outcomes.
For the latest updates and detailed information on OptiNose's financial performance, current projects, and strategic developments, visit their website or follow them on social media platforms like X and LinkedIn.
Optinose (NASDAQ:OPTN) has announced preliminary unaudited XHANCE net product revenue of $22.4 million for Q4 2024. The company reported an estimated 20% sequential prescription growth rate from Q3 to Q4 2024.
CEO Ramy Mahmoud stated that the preliminary Q4 net product revenue aligns with their prior guidance and shows sustained growth in XHANCE prescriptions. The company plans to release full financial results and corporate updates in March.
The company notes that these preliminary results are subject to change pending completion of financial closing procedures, review adjustments, and other developments before the financial results are finalized.
Optinose (NASDAQ: OPTN) has announced a 1-for-15 reverse stock split effective December 30, 2024, at 5:00 p.m. EST. The company's common stock will trade on a split-adjusted basis starting December 31, 2024, under the same symbol 'OPTN' but with a new CUSIP number. This strategic move aims to regain compliance with Nasdaq's $1.00 minimum closing bid price requirement.
The reverse split will reduce outstanding shares from 150,829,507 to approximately 10,055,300. All outstanding options, warrants, and shares reserved for future issuance will be proportionally adjusted. Stockholders will receive cash for any fractional shares based on the closing price on December 30, 2024. The split was approved by stockholders on December 23, 2024, and will not affect stockholders' ownership percentages.
Optinose (NASDAQ:OPTN), a pharmaceutical company specializing in ear, nose and throat (ENT) and allergy treatments, has announced its participation in the Piper Sandler 36th Annual Healthcare Conference. The company's management team will deliver a company overview and business update on December 5, 2024, at 1:30 p.m. ET. The presentation will be accessible via webcast on the Investors page of the Optinose website, with replay availability for 30 days after the event.
Optinose (NASDAQ:OPTN) reported Q3 2024 financial results with XHANCE net revenue of $20.4 million, up 3% from Q3 2023. The company observed a positive inflection in new prescriptions starting September, with October showing a 20-40% increase in weekly new prescriptions. However, the company decreased its full-year 2024 XHANCE net revenue guidance to $75.0-79.0 million from previous $85.0-90.0 million. Operating expenses guidance was reduced to $90.0-93.0 million. The company reported Q3 net income of $0.5 million, while maintaining cash and cash equivalents of $82.5 million as of September 30, 2024.
Optinose (NASDAQ:OPTN), a pharmaceutical company focused on ENT and allergy specialists, has scheduled its third quarter 2024 financial results announcement for Tuesday, November 12, 2024, before market open. The company will host a conference call at 8:00 a.m. Eastern Time on the same day, featuring its leadership team who will discuss financial results and corporate updates. Interested participants can join via webcast through the company's investor relations website or register for telephone access. A replay will be available for 60 days following the event.
Optinose (NASDAQ:OPTN), a pharmaceutical company specializing in ENT and allergy treatments, has appointed Terry Kohler as Chief Financial Officer. Kohler, previously CFO at Verrica Pharmaceuticals, brings over 20 years of biotech finance experience. CEO Ramy Mahmoud emphasized Kohler's expertise in financial strategy for commercial-stage branded pharmaceuticals, which will be valuable for maximizing XHANCE's potential in treating chronic rhinosinusitis.
Kohler expressed enthusiasm about joining Optinose during XHANCE's transition towards a new indication with significant potential. His background includes roles at Endo International PLC and participation in Johnson & Johnson's MBA Leadership Development program. As part of his appointment, Kohler received a non-qualified stock option for 675,000 shares at $0.71 per share and 150,000 restricted stock units, subject to vesting conditions.
Optinose (NASDAQ:OPTN) announced the peer-reviewed publication of a paper in the International Forum of Allergy & Rhinology, highlighting the benefits of XHANCE in chronic rhinosinusitis (CRS) patients. The study, based on two 24-week randomized trials (ReOpen1 and ReOpen2), evaluated XHANCE versus EDS-placebo in CRS patients with and without prior sinus surgery.
Key findings include:
- XHANCE improved symptoms, sinus opacification, and quality of life in both groups
- Previous surgery is not required for CRS patients to benefit from XHANCE
- XHANCE can be helpful for patients even after surgery
The Exhalation Delivery System™ with fluticasone (EDS-FLU; XHANCE) creates unique biomechanics that enable deposition of corticosteroid into sinuses and sinus drainage pathways, proving effective for treating chronic sinusitis without nasal polyps.
Optinose (NASDAQ:OPTN), a pharmaceutical company specializing in treatments for ear, nose, and throat (ENT) and allergy patients, has announced its participation in the H.C. Wainwright 26th Annual Global Investment Conference. The company's management team will deliver a presentation on September 9, 2024, at 10:00 a.m. ET, providing a comprehensive overview of the company and updates on its business operations.
Investors and interested parties can access a live webcast of the presentation through the Investors page on the Optinose website. For those unable to attend the live event, a replay of the webcast will be available for 30 days following the conference.
Optinose (NASDAQ:OPTN) reported Q2 2024 financial results, with XHANCE net revenue of $20.5 million, a 5% increase from Q2 2023. The company narrowed its full-year 2024 XHANCE net revenue guidance to $85.0-$90.0 million and increased expected average net revenue per prescription to at least $250. Notably, XHANCE was added to Express Scripts' national formularies, covering over 24 million lives. Optinose completed a $55 million registered direct offering, extending its cash runway through 2025. The company reported a net loss of $7.6 million for Q2 2024. Optinose continues to focus on its new first-and-only label indication for chronic sinusitis, which expands its total addressable market.
Optinose (NASDAQ:OPTN), a pharmaceutical company focused on ear, nose and throat (ENT) and allergy treatments, has announced its plans to report second quarter 2024 financial results and corporate updates. The company will release this information before market open on Thursday, August 8, 2024. Following the release, Optinose will host a conference call and webcast at 8:00 a.m. Eastern Time on the same day.
Investors and interested parties can access the live webcast through the Investors section of Optinose's website. For those wishing to participate via telephone, pre-registration is required. A replay of the webcast will be available on the company's website for 60 days after the event.
FAQ
What is the current stock price of Optinose (OPTN)?
What is the market cap of Optinose (OPTN)?
What is OptiNose, Inc.?
What is XHANCE?
What recent approval did OptiNose receive from the FDA?
What is the ReOpen program?
What common side effects are associated with XHANCE?
How does OptiNose's Exhalation Delivery System (EDS) work?
What is chronic rhinosinusitis?
Where is OptiNose headquartered?
How does OptiNose create value for the healthcare system?
Where can I learn more about OptiNose and its products?
